OTCMKTS:CPHRF Cipher Pharmaceuticals (CPHRF) Stock Price, News & Analysis → Automatic Income (from home) (From Awesomely, LLC) (Ad) Free CPHRF Stock Alerts $6.60 +0.07 (+1.07%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$6.49▼$6.6350-Day Range$5.21▼$7.1652-Week Range$2.20▼$7.37Volume11,808 shsAverage Volume17,911 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Cipher Pharmaceuticals alerts: Email Address Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Cipher Pharmaceuticals Stock (OTCMKTS:CPHRF)Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.Read More CPHRF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPHRF Stock News HeadlinesMay 3, 2024 | finance.yahoo.comCipher Pharmaceuticals Schedules Q1 2024 Earnings Release and Conference CallApril 26, 2024 | finance.yahoo.comCipher Pharmaceuticals Inc.'s (TSE:CPH) Stock's On An Uptrend: Are Strong Financials Guiding The Market?May 4, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 19, 2024 | wsj.comCipher Pharmaceuticals Inc.March 16, 2024 | finance.yahoo.comCipher Pharmaceuticals' (TSE:CPH) three-year earnings growth trails the 93% YoY shareholder returnsMarch 14, 2024 | finance.yahoo.comCipher Pharmaceuticals Reports Fourth Quarter and Full Year 2023 ResultsMarch 8, 2024 | finance.yahoo.comCipher Pharmaceuticals Schedules Q4 2023 Earnings Release and Conference CallFebruary 17, 2024 | benzinga.comIs Cipher Stock (CPHRF) a Good Buy?May 4, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. January 29, 2024 | msn.comWill Uplisting Be the Catalyst to Send Sharesof this Pharma Company Higher?January 29, 2024 | finance.yahoo.comOTC Markets Group Welcomes Cipher Pharmaceuticals Inc. to OTCQXNovember 16, 2023 | ca.finance.yahoo.comCipher Pharmaceuticals Inc. (CPH.TO)November 9, 2023 | finance.yahoo.comCipher Pharmaceuticals Reports Strong Sales & Earnings Growth in Q3 2023October 12, 2023 | finance.yahoo.comCipher Pharmaceuticals Announces Final Results of Substantial Issuer BidOctober 3, 2023 | finance.yahoo.comCipher Pharmaceuticals Provides Reminder of the Upcoming Expiration of its Substantial Issuer BidJune 1, 2023 | markets.businessinsider.comCipher Pharmaceuticals (CPHRF) Receives a Buy from Stifel NicolausMay 17, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc up on Wednesday (CPH)May 11, 2023 | seekingalpha.comCipher Pharmaceuticals GAAP EPS of $0.10 beats by $0.02, revenue of $4.9M misses by $0.64MMay 11, 2023 | finance.yahoo.comCipher Pharmaceuticals Reports First Quarter Results, Highlighted by Record Cash Per Share and Strong Financial FlexibilityMay 2, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc down on Tuesday (CPH)May 2, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc up on Monday (CPH)April 27, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc down on Thursday (CPH)April 21, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc down on Friday (CPH)April 7, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc up on Thursday (CPH)March 20, 2023 | seekingalpha.comCipher Pharmaceuticals Inc. (CPHRF) Q4 2022 Earnings Call TranscriptMarch 17, 2023 | markets.businessinsider.comCipher Pharmaceuticals earnings: here's what Wall Street expectsMarch 10, 2023 | finance.yahoo.comCipher Pharmaceuticals Schedules Q4 2022 Earnings Release and Conference CallSee More Headlines Receive CPHRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/05/2016Today5/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:CPHRF Previous SymbolNASDAQ:CPHR CUSIPN/A CIKN/A Webwww.cipherpharma.com Phone(905) 602-5840FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Craig J. MullInterim CEO & Chairman of the BoardMr. Bryan JacobsChief Financial OfficerDr. Diane GajewczykVice President of Scientific & Medical AffairsMr. Emilio PrestiDirector of Sales & MarketingKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors CPHRF Stock Analysis - Frequently Asked Questions Should I buy or sell Cipher Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CPHRF shares. View CPHRF analyst ratings or view top-rated stocks. How have CPHRF shares performed in 2024? Cipher Pharmaceuticals' stock was trading at $4.19 on January 1st, 2024. Since then, CPHRF stock has increased by 57.5% and is now trading at $6.60. View the best growth stocks for 2024 here. Are investors shorting Cipher Pharmaceuticals? Cipher Pharmaceuticals saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 13,100 shares, a decline of 16.6% from the March 31st total of 15,700 shares. Based on an average daily volume of 33,500 shares, the short-interest ratio is currently 0.4 days. View Cipher Pharmaceuticals' Short Interest. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) posted its earnings results on Thursday, May, 5th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.06. The business earned $9.10 million during the quarter, compared to the consensus estimate of $10.87 million. How do I buy shares of Cipher Pharmaceuticals? Shares of CPHRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CPHRF) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchStock-Picking AI Predicts #1 Stock of 2024AltimetryHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceThe asset beating inflation by 4xColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.